Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.

Browse

Order by:     Display #  

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>


Merck & Co., Inc.: PharmaVitae Profile
This analysis examines the historical and forecast performance for Merck & Co. in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 yea

$5 700.00    Product Details...


Genentech Inc.: PharmaVitae Profile
Analysis of Genentech’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

$5 700.00    Product Details...


Les Laboratoires Servier: PharmaVitae Profile 2008
Analysis of Servier’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

$5 700.00    Product Details...


Shire plc: PharmaVitae Profile
This analysis examines the historical and forecast performance for Shire in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sale

$5 700.00    Product Details...


Wyeth: PharmaVitae Profile 2008
Analysis of Wyeth’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

$5 700.00    Product Details...


Pfizer Inc.: PharmaVitae Profile 2008
Analysis of Pfizer’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

$5 700.00    Product Details...


Almirall: PharmaVitae Profile
This analysis examines the historical and forecast performance for Almirall in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year s

$5 700.00    Product Details...


Mitsubishi Tanabe Pharma Corporation: PharmaVitae Profile
This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year

$5 700.00    Product Details...


Eli Lilly & Co.: PharmaVitae Profile 2006
This analysis examines the historical and forecast performance for Eli Lilly in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year

$5 700.00    Product Details...


Allergan Inc.: PharmaVitae Profile
This analysis examines the historical and forecast performance for Allergan in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year s

$5 700.00    Product Details...


Les Laboratoires Servier: PharmaVitae Profile 2007
This analysis examines the historical and forecast performance for Servier in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sa

$5 700.00    Product Details...


Abbott Laboratories: PharmaVitae Profile 2008
Analysis of Abbott’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

$5 700.00    Product Details...


Sepracor Inc.: PharmaVitae Profile 2008
Analysis of Sepracor’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

$5 700.00    Product Details...


Schering-Plough Corporation: PharmaVitae Profile
Analysis of Schering-Plough’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

$5 700.00    Product Details...


Takeda Pharmaceutical Co., Ltd: PharmaVitae Profile
This analysis examines the historical and forecast performance for Takeda in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sal

$5 700.00    Product Details...


Ipsen: PharmaVitae Profile
This analysis examines the historical and forecast performance for Ipsen in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sale

$5 700.00    Product Details...


Cephalon Inc.: PharmaVitae Profile
This analysis examines the historical and forecast performance for Cephalon in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year s

$5 700.00    Product Details...


Astellas Pharma Inc.: PharmaVitae Profile
This analysis examines the historical and forecast performance for Shionogi in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year s

$5 700.00    Product Details...


Watson: PharmaVitae Generics Profile
This analysis examines the historical and forecast performance for Watson in the generic pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sal

$3 800.00    Product Details...


Daiichi Sankyo Co., Ltd: PharmaVitae Profile
This analysis examines the historical and forecast performance for Daiichi Sankyo in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sal

$5 700.00    Product Details...


Abbott Laboratories: PharmaVitae Profile 2007
This analysis examines the historical and forecast performance for Abbott in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sal

$5 700.00    Product Details...


F. Hoffmann-La Roche Ltd.: PharmaVitae Profile
Analysis of Roche’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

$5 700.00    Product Details...


Merck KGaA: PharmaVitae Profile
Analysis of Merck KGaA’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

$5 700.00    Product Details...


Solvay S.A.: PharmaVitae Profile 2007
This analysis examines the historical and forecast performance for Solvayin the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sale

$5 700.00    Product Details...


Bayer Schering Pharma AG: PharmaVitae Profile 2008
Analysis of Bayer Schering Pharma’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

$5 700.00    Product Details...


Genzyme Corporation: PharmaVitae Profile 2008
Analysis of Genzyme’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

$5 700.00    Product Details...


Bristol-Myers Squibb Co.: PharmaVitae Profile 2008
Analysis of Bristol-Myers Squibb’s corporate strategy, marketed portfolio, pipeline potential and financial position in 2007 and to 2013

$5 700.00    Product Details...


Genzyme Corporation: PharmaVitae Profile 2007
This analysis examines the historical and forecast performance for Genzyme in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sa

$5 700.00    Product Details...


Bristol-Myers Squibb: PharmaVitae Profile
This analysis examines the historical and forecast performance for BMS in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales

$5 700.00    Product Details...


Eisai Co., Ltd: PharmaVitae Profile
This analysis examines the historical and forecast performance for Eisai in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sale

$5 700.00    Product Details...